Our Team
Mark Reid
Founder and Managing Director
Mark Reid established Graythan Regulatory Services in 2017. Mark is a pharmaceutical regulatory strategist with over 25 years of experience globally and five RAC certifications spanning Canada, the EU, the US, and globally.
As Co-Founder and Managing Director of GRS, he leads a specialist consultancy spanning medical devices, pharmaceuticals, biologics, cell and gene therapy. He has worked in NATA-certified laboratories (ISO 17025, ISO 9001) as a virologist, clinical investigator, and regulatory consultant in Europe and Australia advising clients in preclinical and clinical planning for their NCEs and biologicals. Mark has served as CEO and Managing Director of an international pharmaceutical company with subsidiaries in Australia, Ireland and the USA.
Mark is a Graduate of the Australian Institute of Company Directors, holds an Executive MBA and have overseen product launches in over 34 countries under his leadership with significant returns on investment. He brings real-world executive and board experience to his clients seeking to build value in their portfolio and exit.
Barbara Kienast
Head of Clinical Operations and Regulatory Affairs, Quality Assurance Manager
Barbara has over 25 years of international experience, living in six countries and speaking three languages. Barbara is Secretary of the GRS IBC and has managed multiple GMO studies including CTA studies. Barbara has extensive clinical QA experience and has worked across all clinical trial phases and a range of therapeutic areas including cardiology, ear disorders, endocrinology & vaccine, genetic disorders, vaccine, ophthalmology, neurology, respiratory, transplant, oncology, infectious disease, and musculoskeletal.
Barbara is a well-organised and cooperative individual who works efficiently. Barbara is a Chemical Engineer by training with a PMP qualification.
Dr Kym Lowry
Co-Founder & Chief Scientific Officer, Quality Assurance Manager
Dr Kym Lowry is a molecular virologist with over two decades of experience spanning infectious disease research, molecular diagnostics, and GMO expertise. She holds a PhD in Virology from the University of Warwick, England and a Bachelor of Applied Science in Biotechnology and Microbiology.
As a part-time Postdoctoral Research Fellow at a top 50 global University, Kym maintains an active research and publication record across virology, genomics, diagnostics, and emerging infectious diseases. Within GRS, Kym provides scientific leadership across biosafety governance, GMO regulatory strategy including membership of the GRS IBC. She has extensive experience in NATA-accredited laboratory environments (ISO 17025 and ISO 15189) and co-founded a global antimalarial pharmaceutical company focused on sterile injectable medicines.
Kym brings the rare ability to bridge rigorous bench science with practical regulatory and quality frameworks a cornerstone of the GRS scientific offering.
Choose Graythan to ensure the success of your drug development program
At Graythan, we strive to add value to our client’s drug development programs through expert advice on regulatory and commercialisation pathways and by facilitation of regulatory processes.
Talk to us today about how we can make a difference with your drug development program, and make it a success.
Extensive Knowledge
Our many talented people have up-to-date in-depth knowledge of the life sciences industry
Our Journey
We work closely with you to guarantee our services are tailored to your company’s specific needs
Proven Results
We have a strong track record of success, coupled with high client retention rates and quality assurance
Personalised Support
Each client has their own GRS Consultant who ensures your needs are met to ensure product success